This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.
The report includes:
- 46 data tables and 12 additional tables
- An overview of the global markets for pharmaceutical treatments for mental health disorders
- Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions
- A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
- Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
- Information on tele mental health software such as ReSet, Pears Somryst and Alkili’s EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
- Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
- Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
- Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Depression and Anxiety
- Market Landscape
- Segmentation by Drug Class
- Segmentation by Company
- Prevalence of Disorders
- Diagnosis
- Current Treatments
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
- Tricyclic Antidepressants (TCAs)
- Monoamine Oxidase Inhibitors (MAOIs)
- Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs)
- Benzodiazepines
- Recent Drug Developments
- Drug/Company
- Late-Stage Drug Failures/Withdrawals
- Drugs in Clinical Development to Treat Depression
- Phase 3 Drugs in Development to Treat Depression
- Phase 2 Drugs in Development to Treat Depression
- Drugs in Clinical Development to Treat Anxiety
- Phase 3 Drugs in Development to Treat Anxiety
- Phase 2 Drugs in Development to Treat Anxiety
- Alternative Approaches
- Digital Therapeutics
- M&A Activity
- Future Opportunities
Chapter 4 Attention Deficit Hyperactivity Disorder
- Market Landscape
- Segmentation by Geography
- Segmentation by Drug Class
- Segmentation by Company
- Prevalence
- Diagnosis
- Current Treatments
- Recent Drug Developments
- Drugs/Companies
- Late-Stage Drug Failures/Withdrawals
- Drugs in Clinical Development to Treat ADHD
- Phase 3 Drugs in Development to Treat ADHD
- Phase 2 Drugs in Development to Treat ADHD
- Alternative Approaches
- Digital Therapeutics
- M&A Activity
- Future Opportunities
Chapter 5 Schizophrenia
- Market Landscape
- Segmentation by Geography
- Segmentation by Drug Class
- Segmentation by Company
- Prevalence
- Diagnosis
- Current Treatments
- Recent Drug Developments
- Drugs/Companies
- Late-Stage Drug Failures/Withdrawals
- Drugs in Clinical Development to Treat Schizophrenia
- Phase 3 Drugs in Development to Treat Schizophrenia
- Phase 2 Drugs in Development to Treat Schizophrenia
- Alternative Approaches
- Digital Therapeutics
- M&A Activity
- Future Opportunities
Chapter 6 Substance Use Disorders
- Market Landscape
- Segmentation by Geography
- Segmentation by Drug Class
- Segmentation by Company
- Prevalence
- Diagnosis
- Current Treatments
- Opioid Use Disorders
- Alcohol Use Disorders
- Nicotine Use Disorders
- Recent Drug Developments
- Drugs in Clinical Development to Substance Abuse Disorder
- Phase 3 Drugs in Development to Treat Substance Use Disorders
- Phase 2 Drugs in Development to Treat Substance Use Disorder
- Alternative Approaches
- Digital Therapeutics
- M&A Activity
- Future Opportunities
Chapter 7 Company Profiles
- Pharmaceutical Companies
- Abbvie
- Alkermes Plc
- Astrazeneca Plc
- Boehringer Ingelheim International Gmbh
- Eli Lilly & Co.
- Glaxosmithkline Plc
- H Lundbeck A/S
- Johnson & Johnson
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Shionogi & Co. Ltd.
- Takeda Pharmaceuticals Co. Ltd.
- Specialty Pharma And Biotechs
- Acadia Pharmaceuticals Inc.
- Adamis Pharmaceuticals Corp.
- Bioxcel Therapeutics Inc.
- Intra-Cellular Therapies Inc.
- Intervexion Therapeutics
- Ironshore Pharmaceuticals
- Kempharm Inc.
- Minerva Neurosciences Inc.
- Neos Therapeutics Inc.
- NLS Pharmaceutical Ag
- Noven Pharmaceuticals Inc.
- Sage Therapeutics
- Supernus Pharmaceuticals, Inc.
- Tonix Pharmaceuticals Holdings Corp.
- Tris Pharma Inc.
- Digital Therapeutic Companies
- Orexo Ab
- Pear Therapeutics
List of Tables
Summary Table: Global Market for Drugs Prescribed to Treat Mental Health Disorders, by Type of Disorder, Through 2025
Table 1: Drugs in Phase 3 Development for Selected Psychiatric Disorders
Table 2: Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025
Table 3: Global Market for Brand Name Drugs Prescribed to Treat Depression and Anxiety, by Leading Drug/Company, Through 2025
Table 4: Global Market for Drugs Prescribed to Treat Depression and Anxiety, by Leading Company/Manufacturer
Table 5: Drug Profiles of Leading Approved Antidepressants
Table 6: Drugs Recommended for the Treatment of Anxiety
Table 7: Drugs in Clinical Development to Treat Depression
Table 8: Global Market for New Drugs Prescribed to Treat Depression, by Drug/Company, Through 2025
Table 9: Drugs in Clinical Development to Treat Anxiety Disorders
Table 10: Global Market for New Brand Name Drugs Prescribed to Treat Anxiety, by Drug/Company
Table 11: Global Market for Digital Therapeutics, by Drug/Company, Through 2025
Table 12: Digital Therapeutics in Clinical Development for CNS Disorders
Table 13: Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025
Table 14: Global Market for Drugs Prescribed to Treat ADHD, Through 2025
Table 15: Global Market for Drugs Prescribed to Treat ADHD, by Region, Through 2025
Table 16: Global Market for Leading Brand Name Drugs Prescribed to Treat ADHD, by Drug/Company, Through 2025
Table 17: Global Market for Drugs Prescribed to Treat ADHD, by Leading Company/Manufacturer, Through 2025
Table 18: Drug Profiles of Leading Approved ADHD Treatments
Table 19: ADHD Drug Profiles
Table 20: Drugs in Clinical Development to Treat ADHD
Table 21: Global Market for New Drugs Prescribed to Treat ADHD, by Drug/Company, Through 2025
Table 22: Global Market for Digital Therapeutics, Through 2025
Table 23: Global Market for Drugs Prescribed to Treat ADHD, Through 2025
Table 24: Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025
Table 25: Global Market for Drugs Prescribed to Treat Schizophrenia, by Region, Through 2025
Table 26: Global Market for Leading Brand Name Drugs Prescribed to Treat Schizophrenia, by Drug/Company, Through 2025
Table 27: Global Market for Drugs Prescribed to Treat Schizophrenia, by Leading Company, Through 2025
Table 28: Drugs in Clinical Development to Treat Schizophrenia
Table 29: Drugs in Clinical Development to Treat Bipolar Disorder
Table 30: Global Market for New Drugs Prescribed to Treat Schizophrenia, Through 2025
Table 31: Global Market for Digital Therapeutics to Treat Schizophrenia, Through 2025
Table 32: Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025
Table 33: Global Market for Drugs Prescribed to Treat Substance Use Disorders, Through 2025
Table 34: Global Market for Drugs Prescribed to treat Substance Use Disorders, by Region, Through 2025
Table 35: Global Market for Leading Brand Name Drugs Prescribed to Treat Substance Use Disorders, by Drug/Company, Through 2025
Table 36: Global Market for Drugs Prescribed to Treat Substance Use Disorders, by Leading Company, Through 2025
Table 37: Prevalence of Substance Use Disorders across the Globe, by Economy, 1990 vs. 2017
Table 38: Drugs in Clinical Development to Treat Substance Use Disorder
Table 39: Global Market for New Drugs to Treat Substance Abuse Disorders, by Drug/Company Through 2025
Table 40: Global Market for Digital Therapeutics, by Drug/Company, 2019-2025
Table 41: Global Market for Drugs Precribed to Treat Substance Use Disorders, Through 2025
Table 42: AbbVie Revenue, 2017–2020
Table 43: Alkermes Revenue, 2017–2020
Table 44: AstraZeneca Revenue, 2017–2020
Table 45: Boehringer Ingelheim Revenue, 2019
Table 46: Eli Lilly Revenue, 2017–2020
Table 47: GlaxoSmithKline Revenue, 2017–2020
Table 48: H Lundbeck A/S Revenue, 2017–2020
Table 49: Johnson & Johnson Revenue, 2017–2020
Table 50: Otsuka Revenue, 2017–2020
Table 51: Pfizer Revenue, 2017–2020
Table 52: Shionogi Revenue, Through 2019
Table 53: Takeda Revenue, 2017–2020
Table 54: ACADIA Pharmaceuticals Revenue, 2017–2020
Table 55: Supernus Pharmaceuticals Revenue, 2017–2020
Table 56: Tonix Pharmaceuticals Revenues, 2017–2020
Table 57: Orexo Therapeutics Revenue, Through 2019
List of Figures
Summary Figure: Global Market for Drugs Prescribed to Treat Mental Health Disorders, by Type of Disorder, 2019-2025
Figure 1: Prevalence of Depressive Disorders, by Region
Figure 2: Prevalence of Anxiety Disorders, by Region
Figure 3: AXS-05 Mechanism of Action
Figure 4: DSM Criteria for ADHD
Figure 5: Prevalence of ADHD Subtypes, by Age Group
Figure 6: Development Timelines of Leading ADHD Drugs
Figure 7: Prevalence of Schizophrenia Population, by Sex
Figure 8: Share of the Population with an Alcohol or Drug Use Disorder, 2016
Figure 9: People with Substance Use Disorder and Mental Health Disorder
Samples
LOADING...
Executive Summary
It is estimated that mental health disorders affect one in four adults each year and are the leading cause of impairment and disability across the globe. Mental health disorders refer to a wide range of mental health disorders that affect mood, thinking and behavior. These conditions can occur either due to biological factors such as anatomical, chemical and genetic traits, or psychological reasons such as conflict or trauma.
Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COIVD-19 pandemic, social distancing and social isolation.
Reasons for Doing This Study:
The treatment of mental health disorders is complex and often involves pharmacological and behavioral interventions. Diagnosis can be challenging, as symptoms can be complicated by comorbid conditions. This report highlights the current diagnosis and treatment of leading mental health disorders and highlights the clinical unmet needs that new formulations, treatment combinations and new mechanisms of action to address or change the future treatment paradigm of these prevalent conditions. There are also several external factors, including changing regulatory guidance and the impact of the COVID-19 pandemic, which may increase access and reimbursement to medication and digital therapeutics to address unmet medical needs.
Companies Mentioned
- Abbvie
- Acadia Pharmaceuticals Inc.
- Adamis Pharmaceuticals Corp.
- Alkermes Plc
- Astrazeneca Plc
- Bioxcel Therapeutics Inc.
- Boehringer Ingelheim International Gmbh
- Eli Lilly & Co.
- Glaxosmithkline Plc
- H Lundbeck A/S
- Intervexion Therapeutics
- Intra-Cellular Therapies Inc.
- Ironshore Pharmaceuticals
- Johnson & Johnson
- Kempharm Inc.
- Minerva Neurosciences Inc.
- Neos Therapeutics Inc.
- NLS Pharmaceutical Ag
- Noven Pharmaceuticals Inc.
- Orexo Ab
- Otsuka Holdings Co. Ltd.
- Pear Therapeutics
- Pfizer Inc.
- Sage Therapeutics
- Shionogi & Co. Ltd.
- Specialty Pharma And Biotechs
- Supernus Pharmaceuticals, Inc.
- Takeda Pharmaceuticals Co. Ltd.
- Tonix Pharmaceuticals Holdings Corp.
- Tris Pharma Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 128 |
| Published | February 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 49.4 Billion |
| Forecasted Market Value ( USD | $ 62.6 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
